{"product_id":"progyny-five-forces-analysis","title":"Progyny Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eProgyny faces moderate bargaining power from large corporate buyers and payers, high competitive rivalry among fertility benefit managers and clinics, and evolving substitute threats from alternative fertility solutions and telehealth innovations.\u003c\/p\u003e\n\u003cp\u003eSupplier power is tempered by clinic fragmentation but constrained by specialized medical services, while regulatory and technological barriers limit new entrants—yet capital-light digital competitors could disrupt pricing and margins.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Progyny’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Premier Fertility Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProgyny depends on a curated network of ~150 high-performing fertility clinics that drive \u0026gt;70% of successful outcomes; this concentration gives premier clinics leverage despite Progyny’s referral volume. Top-tier reproductive specialists have limited capacity—average wait times rose to 8–12 weeks in 2024—so clinics can sustain premium pricing. By end-2025, estimated shortfall of 2,500 reproductive endocrinologists in the U.S. keeps supplier bargaining power high. Higher clinic pricing pressures Progyny’s unit economics unless offset by negotiated bundles or volume discounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialized Pharmaceutical Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProgyny Rx relies on a handful of specialized pharma firms for biologic fertility drugs, and with biologics making up roughly 70% of IVF drug spend industry-wide (2024 IQVIA), supplier concentration gives makers strong pricing power.\u003c\/p\u003e\n\u003cp\u003eFew generics exist for these high-cost injectables; in 2024 average cycle drug costs exceeded $3,500, so manufacturer price hikes or supply disruptions can compress Progyny’s pharmacy-margin and raise client costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Specialized Medical Professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe supply of board-certified reproductive endocrinologists in North America is tight—AAMC data show a \u0026lt;10% annual increase in demand for fertility care vs ~1–2% supply growth—letting specialists and clinic directors push for higher pay and better referral terms; Progyny reported provider network margins pressured in 2024, and as it expands geographically, securing specialists at sustainable cost will be a key bottleneck to scaling operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological and Data Infrastructure Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProgyny relies on advanced analytics and telehealth platforms to track outcomes; in 2024 its platform processed over 120,000 patient interactions, tying clinical success metrics to vendor systems.\u003c\/p\u003e\n\u003cp\u003eVendors hold leverage via high switching costs, strict HIPAA (HIPAA: Health Insurance Portability and Accountability Act) obligations, and estimated migration costs exceeding $5–10M plus 6–12 months of operational risk.\u003c\/p\u003e\n\u003cp\u003eAny supplier change risks data migration failures, service disruption, and regulatory exposure, making supplier power materially high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ patient interactions (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated migration cost $5–10M\u003c\/li\u003e\n\u003cli\u003eSwitch time 6–12 months\u003c\/li\u003e\n\u003cli\u003eHigh HIPAA compliance risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Competition for Patient Care Advocates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProgyny’s high-touch Patient Care Advocates are central to its fertility benefit; demand for skilled healthcare coordinators grew 12% in the US healthcare workforce from 2019–2024, giving these workers collective leverage to push wages up.\u003c\/p\u003e\n\u003cp\u003eTo keep quality and avoid costly turnover—average replacement cost per clinical staff is 20–30% of annual salary—Progyny must invest in pay, training, and retention, squeezing margins or raising prices.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocate-dependent model increases supplier (labor) power\u003c\/li\u003e\n\u003cli\u003eUS coordinator workforce +12% (2019–2024)\u003c\/li\u003e\n\u003cli\u003eReplacement cost 20–30% of salary\u003c\/li\u003e\n\u003cli\u003eRequires higher labour spend, impacts margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinic \u0026amp; biologic concentration, long waits and high migration costs squeeze Progyny margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert high bargaining power: ~150 clinics drive \u0026gt;70% outcomes, 8–12 week waits (2024), projected shortfall of 2,500 REIs by end-2025, and biologics = ~70% of IVF drug spend (IQVIA 2024); clinic and drug concentration, scarce patient‑care advocates, high switching\/migration costs ($5–10M, 6–12 months), and average cycle drug cost \u0026gt;$3,500 compress Progyny’s margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics driving outcomes\u003c\/td\u003e\n\u003ctd\u003e~150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e% outcomes from network\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREI shortfall (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWait times (2024)\u003c\/td\u003e\n\u003ctd\u003e8–12 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics share of drug spend (2024)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg cycle drug cost (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigration cost \/ time\u003c\/td\u003e\n\u003ctd\u003e$5–10M \/ 6–12 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient interactions (2024)\u003c\/td\u003e\n\u003ctd\u003e120,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Progyny that uncovers competitive drivers, supplier and buyer power, threat of entry and substitutes, and identifies disruptive forces and strategic levers to protect and grow market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces tailored to Progyny—instantly highlight competitive threats and partnership opportunities to streamline strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeverage of Large Self-Insured Employers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge self-insured employers—Progyny’s primary customers—hold strong leverage, often covering 5,000–100,000 employees and negotiating steep volume discounts and bespoke reporting for utilization and outcomes.\u003c\/p\u003e\n\u003cp\u003eThese buyers demand transparent KPIs; in 2024 employer audits of fertility benefits rose ~28%, and clients press for per-member-per-year pricing tied to clinical success and total cost of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Health Insurance Carriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProgyny relies on partnerships with large health plans, but consolidation concentrates distribution power: the top five US carriers (UnitedHealth, Anthem, Aetna\/CVS, Cigna, Humana) covered about 70% of employer-based insured lives in 2024, so carriers can demand deeper discounts or exclusivity.\u003c\/p\u003e\n\u003cp\u003eIf a major carrier builds an internal fertility program, Progyny’s addressable market to mid-to-large employers could shrink materially; a 2023 Willis Towers Watson survey found 48% of employers prefer carrier-managed benefits, raising churn risk for vendors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Sensitivity to Benefit Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025, 62% of surveyed HR buyers report tighter budgets and demand transparent pricing for specialized benefits; many threaten switching to lower-cost, digital-only fertility vendors if premiums rise more than 8% year-over-year. This forces Progyny to tie its higher clinical success—reported 35% greater live-birth rates in employer cohorts—to total-cost-of-care savings, often shown as 12–18% lower downstream maternity and infertility spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Global Benefit Parity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMultinational employers now demand uniform fertility benefits across regions, forcing Progyny to scale international operations quickly or risk losing deals to competitors with established global footprints like Carrot and Maven; 62% of Fortune 500 companies reported pushing for global parity in 2024, per Mercer.\u003c\/p\u003e\n\u003cp\u003eCustomers leverage global scale to negotiate multi-jurisdictional coverage, driving price pressure and requiring Progyny to meet diverse regulatory, reimbursement, and data‑privacy rules across 30+ target markets to retain contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of Fortune 500 want global parity (Mercer 2024)\u003c\/li\u003e\n\u003cli\u003eCompetitors with global presence: Carrot, Maven\u003c\/li\u003e\n\u003cli\u003eNeeds compliance across 30+ markets\u003c\/li\u003e\n\u003cli\u003eRaises price and operational pressure on Progyny\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Benefit Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmployers now choose from reimbursement-only accounts, direct-to-clinic deals, and specialty vendors, cutting reliance on managed-care fertility models and raising buyer power.\u003c\/p\u003e\n\u003cp\u003eUnbundling lets employers pick IVF, egg-freezing, or benefits administration separately, boosting leverage at renewals; 2024 surveys show 38% of employers offered at least one alternative model and plan-switching rose 14% year-over-year.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: if 40% of renewals face multi-vendor bids, Progyny’s pricing leverage falls accordingly—so retention must hinge on measurable outcomes and integration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e38% of employers used alternative models in 2024\u003c\/li\u003e\n\u003cli\u003e14% increase in plan-switching YoY\u003c\/li\u003e\n\u003cli\u003eMulti-vendor bidding in ~40% of renewals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmployers Demand Outcome-Tied Fertility Pricing as Multi-Vendor Bids Rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge self-insured employers and consolidated carriers exert high leverage, demanding outcome-tied pricing, audits, and global parity; 2024–25 data: 62% Fortune 500 want global parity (Mercer 2024), 48% prefer carrier-managed benefits (Willis Towers Watson 2023), 38% used alternative models in 2024; multi-vendor bids hit ~40% of renewals, pressuring Progyny to prove 12–18% total-cost savings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFortune 500 demand\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrefer carrier-managed\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlt models used\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulti-vendor renewals\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaimed TCoC savings\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eProgyny Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Progyny Porter's Five Forces Analysis you'll receive—fully formatted, professionally written, and ready for immediate download upon purchase with no placeholders or mockups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747448336761,"sku":"progyny-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/progyny-five-forces-analysis.png?v=1772198602","url":"https:\/\/matrixbcg.com\/products\/progyny-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}